Microfluidic-Based Manufacture of siRNA-Lipid Nanoparticles for Therapeutic Applications


Authors: C. Walsh, K. Ou, N.M. Belliveau, T.J. Leaver, A.W. Wild, J. Huft, P.J. Lin, S. Chen, A.K. Leung, J.B. Lee, C.L. Hansen, R.J. Taylor, E.C. Ramsay and P.R Cullis

Journal: Methods in Molecular Biology

DOI: 10.1007/978-1-4939-0363-4_6

Publication - Abstract

February 03, 2014

siRNA Nucleic Acid Lipid Nanoparticles Genetic Medicine

Abstract:

A simple, efficient, and scalable manufacturing technique is required for developing siRNA-lipid nanoparticles (siRNA-LNP) for therapeutic applications. In this chapter we describe a novel microfluidic-based manufacturing process for the rapid manufacture of siRNA-LNP, together with protocols for characterizing the size, polydispersity, RNA encapsulation efficiency, RNA concentration, and total lipid concentration of the resultant nanoparticles.


limit search to this category
Advanced Search

Advanced Search

close
  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Articles
Search

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
    • Cell therapy
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads


related content

Publication - Abstract

Dec 06, 2018
Advanced Drug Delivery Reviews

Engineering Lymphocytes with RNAi

S. Ramishetti and D. Peer

Oncology Nucleic Acid Lipid Nanoparticles siRNA
Lymphocytes are the gatekeepers of the body's immune system and are involved in pathogenesis if their surveillance is stalled by inhibitory molecules or when they act as mediators for viral entry. Engineering lymphocytes in order to restore their functions is an unmet need in imm...
Read More


Publication - Abstract

Jun 13, 2018
Journal of Nucleic Acids

SERPINA1 mRNA as a Treatment for Alpha-1 Antitrypsin Deficiency

B. Connolly, C. Isaacs, L. Cheng, K.H. Asrani and R.R. Subramanian

mRNA Nucleic Acid Lipid Nanoparticles Genetic Medicine

Alpha-1-antitrypsin (AAT) deficiency is a genetic disorder that produces inactive/defective AAT due to mutations in the SERPINA1 gene encoding AAT. This disease is associated with decreased activity of AAT in the lungs and deposition of excessive defective AAT protein in the l...

Read More


Sign Up and Stay Informed
Sign up today to automatically receive new Cytiva, formerly Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.
Sign Up